InnoPharmax Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 46.07 million compared to TWD 29.13 million a year ago. Net loss was TWD 70.83 million compared to TWD 103.18 million a year ago.

Basic loss per share from continuing operations was TWD 0.77 compared to TWD 1.19 a year ago. Diluted loss per share from continuing operations was TWD 0.77 compared to TWD 1.19 a year ago.